Literature DB >> 15630425

Cellular immunotherapy for viral infection after HSC transplantation.

Paul Moss1, Alan Rickinson.   

Abstract

Medical advances such as allogeneic transplantation can expose patients to periods of marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Control of infection will depend ultimately on the restoration of adequate antiviral immunity, and cellular immunotherapy is an attractive approach to improving immune protection. Developments in basic immunology have led to a greater understanding of the nature of protective immunity in immunocompetent donors, and this knowledge is now being used to direct immunotherapeutic protocols. Moreover, immunological techniques that have recently been developed as research tools, such as peptide-HLA tetramers and cytokine-secretion assays, have potential application for clinical use in this setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15630425     DOI: 10.1038/nri1526

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  43 in total

Review 1.  Photochemical approaches to T-cell activation.

Authors:  Morgan Huse
Journal:  Immunology       Date:  2010-04-06       Impact factor: 7.397

2.  Nasal Wash Cytokines during Respiratory Viral Infection in Pediatric Allogeneic Hematopoietic Cell-Transplant Recipients.

Authors:  Tim Flerlage; Aisha Souquette; E Kaitlynn Allen; Timothy Brahm; Jeremy Chase Crawford; Li Tang; Yilun Sun; Gabriela Maron; Joshua Wolf; Brandon Triplett; Paul G Thomas
Journal:  Am J Respir Cell Mol Biol       Date:  2020-09       Impact factor: 6.914

3.  Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

Authors:  Lisa Marie Serrano; Timothy Pfeiffer; Simon Olivares; Tontanai Numbenjapon; Jennifer Bennitt; Daniel Kim; David Smith; George McNamara; Zaid Al-Kadhimi; Joseph Rosenthal; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

4.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7.

Authors:  Arnold H Bakker; Rieuwert Hoppes; Carsten Linnemann; Mireille Toebes; Boris Rodenko; Celia R Berkers; Sine Reker Hadrup; Wim J E van Esch; Mirjam H M Heemskerk; Huib Ovaa; Ton N M Schumacher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

Review 5.  CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model.

Authors:  Rafaela Holtappels; Verena Böhm; Jürgen Podlech; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2008-03-15       Impact factor: 3.402

Review 6.  T cell therapy in allogeneic stem cell transplantation.

Authors:  J H Frederik Falkenburg; Helen E Heslop; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

7.  IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection.

Authors:  David G Brooks; Sang-Jun Ha; Heidi Elsaesser; Arlene H Sharpe; Gordon J Freeman; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

8.  Granzyme M targets host cell hnRNP K that is essential for human cytomegalovirus replication.

Authors:  R van Domselaar; S A H de Poot; E B M Remmerswaal; K W Lai; I J M ten Berge; N Bovenschen
Journal:  Cell Death Differ       Date:  2012-10-26       Impact factor: 15.828

9.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

10.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Authors:  Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.